keyword
MENU ▼
Read by QxMD icon Read
search

Mefloquine

keyword
https://www.readbyqxmd.com/read/28931142/malaria-prevention-strategies-and-recommendations-from-chemoprophylaxis-to-stand-by-emergency-treatment-a-10-year-prospective-study-in-a-swiss-travel-clinic
#1
Rim Boubaker, Annie Hérard Fossati, Pierrette Meige, Catherine Mialet, Chantal Ngarambe Buffat, Jacynthe Rochat, Manisinh Souvannaraj-Blanchant, Mediatrice Uwanyiligira, Francine Widmer, Sylvie Payot, Laurence Rochat, Serge de Vallière, Valérie D'Acremont, Blaise Genton
Background: There are several possible malaria prevention strategies for travellers. In Switzerland, chemoprophylaxis (CP) is recommended for persons visiting areas highly endemic for malaria and stand-by emergency treatment (SBET) for areas with moderate to low risk. Objective: To describe the type of malaria prevention prescribed to travel clinic attendees with a specific focus on changes over time following adaptation of recommendations. Methods: All pre-travel first consultation data recorded between November 2002 and December 2012 were included...
September 1, 2017: Journal of Travel Medicine
https://www.readbyqxmd.com/read/28923866/changing-antimalarial-drug-sensitivities-in-uganda
#2
Stephanie A Rasmussen, Frida G Ceja, Melissa D Conrad, Patrick K Tumwebaze, Oswald Byaruhanga, Thomas Katairo, Samuel L Nsobya, Philip J Rosenthal, Roland A Cooper
Dihydroartemisinin-piperaquine (DP) has demonstrated excellent efficacy for the treatment and prevention of malaria in Uganda. However, resistance to both components of this regimen has emerged in Southeast Asia. The efficacy of artemether-lumefantrine, the first-line regimen to treat malaria in Uganda, has also been excellent, but continued pressure may select for parasites with decreased sensitivity to lumefantrine. To gain insight into current drug sensitivity patterns, ex vivo sensitivities were assessed and genotypes previously associated with altered drug sensitivity were characterized for 58 isolates collected in Tororo, Uganda from subjects presenting in 2016 with malaria from the community or as part of a clinical trial comparing DP chemoprevention regimens...
September 18, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28895080/population-pharmacokinetic-and-pharmacodynamic-modeling-of-artemisinin-resistance-in-southeast-asia
#3
Jesmin Lohy Das, Arjen M Dondorp, Francois Nosten, Aung Pyae Phyo, Warunee Hanpithakpong, Pascal Ringwald, Pharath Lim, Nicholas J White, Mats O Karlsson, Martin Bergstrand, Joel Tarning
Orally administered artemisinin-based combination therapy is the first-line treatment against uncomplicated P. falciparum malaria worldwide. However, the increasing prevalence of artemisinin resistance is threatening efforts to treat and eliminate malaria in Southeast Asia. This study aimed to characterize the exposure-response relationship of artesunate in patients with artemisinin sensitive and resistant malaria infections. Patients were recruited in Pailin, Cambodia (n = 39), and Wang Pha, Thailand (n = 40), and received either 2 mg/kg/day of artesunate mono-therapy for 7 consecutive days or 4 mg/kg/day of artesunate monotherapy for 3 consecutive days followed by mefloquine 15 and 10 mg/kg for 2 consecutive days...
September 11, 2017: AAPS Journal
https://www.readbyqxmd.com/read/28894322/implications-of-changes-to-the-mefloquine-product-monograph
#4
Remington L Nevin
No abstract text is available yet for this article.
July 2017: Canadian Journal of Hospital Pharmacy
https://www.readbyqxmd.com/read/28879898/progressive-multifocal-leukoencephalopathy-in-a-44-year-old-male-with-idiopathic-cd4-t-lymphocytopenia-treated-with-mirtazapine-and-mefloquine
#5
Aruna Nambirajan, Vaishali Suri, Vijay Kataria, Mehar C Sharma, Vinay Goyal
Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the central nervous system caused by the reactivation of John Cunningham virus (JCV) in immunocompromised patients, most commonly in human immunodeficiency virus (HIV) infection, and less commonly in those receiving various immunosuppressive regimens. Prognosis of untreated PML is grave and the mainstay of treatment is the reversal of immunosuppression, usually by institution of antiretroviral drugs in HIV patients and cessation of immunosuppressive therapies in others...
September 2017: Neurology India
https://www.readbyqxmd.com/read/28874682/hydrogen-peroxide-dynamics-in-subcellular-compartments-of-malaria-parasites-using-genetically-encoded-redox-probes
#6
Mahsa Rahbari, Stefan Rahlfs, Jude M Przyborski, Anna Katharina Schuh, Nicholas H Hunt, David A Fidock, Georges E Grau, Katja Becker
Redox balance is essential for the survival, growth and multiplication of malaria parasites and oxidative stress is involved in the mechanism of action of many antimalarial drugs. Hydrogen peroxide (H2O2) plays an important role in redox signalling and pathogen-host cell interactions. For monitoring intra- and subcellular redox events, highly sensitive and specific probes are required. Here, we stably expressed the ratiometric H2O2 redox sensor roGFP2-Orp1 in the cytosol and the mitochondria of Plasmodium falciparum (P...
September 5, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28864033/characterising-the-effect-of-antimalarial-drugs-on-the-maturation-and-clearance-of-murine-blood-stage-plasmodium-parasites-in-vivo
#7
David S Khoury, Deborah Cromer, Trish Elliott, Megan S F Soon, Bryce S Thomas, Kylie R James, Shannon E Best, Rosemary A Aogo, Jessica A Engel, Kate H Gartlan, Jasmin Akter, Ismail Sebina, Ashraful Haque, Miles P Davenport
The artemisinins are the first-line therapy for severe and uncomplicated malaria, since they cause rapid declines in parasitemia after treatment. Despite this, in vivo mechanisms underlying this rapid decline remain poorly characterised. The overall decline in parasitemia is the net effect of drug inhibition of parasites and host clearance, which competes against any ongoing parasite proliferation. Separating these mechanisms in vivo was not possible through measurements of total parasitemia alone. Therefore, we employed an adoptive transfer approach in which C57BL/6J mice were transfused with Plasmodium berghei ANKA strain-infected, fluorescent red blood cells, and subsequently drug-treated...
August 31, 2017: International Journal for Parasitology
https://www.readbyqxmd.com/read/28859963/in-vitro-effects-of-amino-alcohols-on-echinococcus-granulosus
#8
Congshan Liu, Jianhai Yin, Jian Xue, Yi Tao, Wei Hu, Haobing Zhang
Cystic echinococcosis is a globally distributed zoonotic disease, which is caused by the larval stage of Echinococcosus granulosus sensu lato. The chemotherapy of the disease is limited to the use of benzimidazoles. Recently, mefloquine and its analogues, aminoalcohol-carbazole, and some amino alcohol derivatives were reported to display inhibitory effects on parasites. Here, the activities of 130 amino alcohol compounds against E. granulosus were tested on protoscoleces and germinal cells at a concentration of 20μg/ml over a period of three days...
August 28, 2017: Acta Tropica
https://www.readbyqxmd.com/read/28854635/partner-drug-resistance-and-population-substructuring-of-artemisinin-resistant-plasmodium-falciparum-in-cambodia
#9
Christian M Parobek, Jonathan B Parr, Nicholas F Brazeau, Chanthap Lon, Suwanna Chaorattanakawee, Panita Gosi, Eric J Barnett, Lauren D Norris, Steven R Meshnick, Michele D Spring, Charlotte A Lanteri, Jeffrey A Bailey, David L Saunders, Jessica T Lin, Jonathan J Juliano
Plasmodium falciparum in western Cambodia has developed resistance to artemisinin and its partner drugs, causing frequent treatment failure. Understanding this evolution can inform the deployment of new therapies. We investigated the genetic architecture of 78 falciparum isolates using whole-genome sequencing, correlating results to in vivo and ex vivo drug resistance and exploring the relationship between population structure, demographic history, and partner drug resistance. Principle component analysis, network analysis and demographic inference identified a diverse central population with three clusters of clonally expanding parasite populations, each associated with specific K13 artemisinin resistance alleles and partner drug resistance profiles which were consistent with the sequential deployment of artemisinin combination therapies in the region...
June 1, 2017: Genome Biology and Evolution
https://www.readbyqxmd.com/read/28814310/modelling-the-benefits-of-long-acting-or-transmission-blocking-drugs-for-reducing-plasmodium-falciparum-transmission-by-case-management-or-by-mass-treatment
#10
Michael T Bretscher, Jamie T Griffin, Azra C Ghani, Lucy C Okell
BACKGROUND: Anti-malarial drugs are an important tool for malaria control and elimination. Alongside their direct benefit in the treatment of disease, drug use has a community-level effect, clearing the reservoir of infection and reducing onward transmission of the parasite. Different compounds potentially have different impacts on transmission-with some providing periods of prolonged chemoprophylaxis whilst others have greater transmission-blocking potential. The aim was to quantify the relative benefit of such properties for transmission reduction to inform target product profiles in the drug development process and choice of first-line anti-malarial treatment in different endemic settings...
August 16, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28805982/a-serious-nightmare-psychiatric-and-neurologic-adverse-reactions-to-mefloquine-are-serious-adverse-reactions
#11
Remington L Nevin
Mefloquine (originally marketed as Lariam) is a neurotoxic quinoline derivative antimalarial drug that is known to cause serious and potentially lasting neuropsychiatric adverse reactions. Since 2013, drug regulators in several jurisdictions, including the United States, the United Kingdom, Ireland, and Canada, have required their mefloquine labels be updated to warn that when used for malaria prophylaxis the drug should be discontinued at the onset of neurologic or psychiatric symptoms. These recent changes to the international labeling serve to imply that psychiatric and neurologic reactions to mefloquine prophylaxis may be an early warning of an impending more serious reaction that may further jeopardize the patient with continued use of the drug...
August 2017: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/28804147/ismp-adverse-drug-reactions-levofloxacin-induced-neuroexcitation-and-hallucinations-statin-induced-muscle-rupture-mefloquine-induced-rhabdomyolysis-methimazole-induced-cholestatic-hepatitis-decitabine-induced-hand-and-foot-syndrome
#12
Michael A Mancano
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers. Write to Dr. Mancano at ISMP, 200 Lakeside Drive, Suite 200, Horsham, PA 19044 (phone: 215-707-4936; e-mail: mmancano@temple.edu). Your report will be published anonymously unless otherwise requested...
May 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/28774303/comparison-of-anti-malarial-drugs-efficacy-in-the-treatment-of-uncomplicated-malaria-in-african-children-and-adults-using-network-meta-analysis
#13
Solange Whegang Youdom, Rachida Tahar, Leonardo K Basco
BACKGROUND: Artemisinin-based combination therapy (ACT) and novel drug combinations are available and used in African countries to treat uncomplicated malaria. Network meta-analysis methods are rarely and poorly applied for the comparison of their efficacies. This method was applied on a set of randomized controlled trials to illustrate its usefulness. METHODS: A literature review available in Pubmed was conducted in July 2016. Eligible studies, conducted in sub-Saharan Africa, published between 2002 and 2016, focused on randomized controlled trials of at least two artemisinin-based combinations to treat uncomplicated malaria in children and adults...
August 3, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28745231/synthesis-and-antimalarial-activity-of-new-enantiopure-aminoalcoholpyrrolo-1-2-a-quinoxalines
#14
Alexia Jonet, Jean Guillon, Catherine Mullié, Anita Cohen, Guillaume Bentzinger, Jérémy Schneider, Nicolas Taudon, Sebastien Hutter, Nadine Azas, Stephane Moreau, Solene Savrimoutou, Patrice Agnamey, Alexandra Dassonville-Klimpt, Pascal Sonnet
Backgroung: We prepared a novel series of enantiopure mefloquine analogues with pyrrolo[1,2-a]quinoxaline core in order to fight Plasmodium falciparum resistant strain. OBJECTIVES: To observe the influence of pyrrolo[1,2-a]quinoxaline core versus quinoline core on the antimalarial activity. METHOD: Four enantiopure aminoalcoholpyrrolo[1,2-a]quinoxalines 2 were synthetized via Sharpless asymmetric dihydroxylation reaction in eight steps. Their antimalarial activity was evaluated on two Plasmodium falciparum strains 3D7 and W2 with a SYBR Green I fluorescence-based method and their cytotoxicity was measured on four cell lines HepG2, THP-1, CHO and HFF...
July 26, 2017: Medicinal Chemistry
https://www.readbyqxmd.com/read/28738892/challenges-to-replace-act-as-first-line-drug
#15
Aung Pyae Phyo, Lorenz von Seidlein
The spread of artemisinin and partner drug resistance through Asia requires changes in first-line therapy. The traditional modus has been the replacement of one first-line anti-malarial regimen with another. The number of anti-malarial drug candidates currently in development may have given false confidence in the expectation that resistance to artemisinin-based combination therapy (ACT) can be solved with a switch to the next anti-malarial drug regimen. A number of promising anti-malarial drug regimens did not succeed in becoming first-line drugs due to safety concerns or rapid development of resistance...
July 24, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28724002/challenges-in-a-product-development-partnership-a-malaria-treatment-case-study
#16
Vera Lucia Luiza, Gabriela Costa Chaves, Tayná Marques Torres Barboza, Luciana de Paula Barros Gonçalves, Eric G Stobbaerts
This paper examines the development of a treatment - a fixed-dose combination of artesunate and mefloquine - in Brazil, from three points of view: in terms of access to medication; to record and report successes; and to look at the lessons learned. This product development took place in the ambit of a public-private partnership. Semi-structured interviews were held with key actors involved in the different phases of the development, and documents were analyzed. Two important points of reference orienting the design of the study and analysis were: a logical model for access to medication; and evaluation of programs...
July 2017: Ciência & Saúde Coletiva
https://www.readbyqxmd.com/read/28719304/misclassification-and-bias-in-military-studies-of-mefloquine
#17
Remington Lee Nevin
No abstract text is available yet for this article.
July 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28689867/ex-vivo-activity-of-proveblue-a-methylene-blue-against-field-isolates-of-plasmodium-falciparum-in-dakar-senegal-from-2013-2015
#18
Bécaye Fall, Marylin Madamet, Silman Diawara, Sébastien Briolant, Khalifa Ababacar Wade, Gora Lo, Aminata Nakoulima, Mansour Fall, Raymond Bercion, Mame Bou Kounta, Rémi Amalvict, Nicolas Benoit, Mamadou Wague Gueye, Bakary Diatta, Boubacar Wade, Bruno Pradines
Resistance to most antimalarial drugs has spread from Southeast Asia to Africa. Accordingly, new therapies to use with artemisinin-based combination therapy (triple ACT) are urgently needed. Proveblue, a methylene blue preparation, was found to exhibit antimalarial activity against Plasmodium falciparum strains in vitro. Proveblue has synergistic effects when used in combination with dihydroartemisinin, and has been shown to significantly reduce or prevent cerebral malaria in mice. The objectives of the current study were to evaluate the in vitro baseline susceptibility of clinical field isolates to Proveblue, compare its activity with that of other standard antimalarial drugs and define the patterns of cross-susceptibility between Proveblue and conventional antimalarial drugs...
July 6, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28650618/solution-and-solid-state-correlations-of-antimalarial-drug-actions-nmr-and-crystallographic-studies-of-drug-interactions-with-a-heme-model
#19
Erin L Dodd, Dagobert Tazoo, D Scott Bohle
Solution NMR has been used in tandem with a diamagnetic non-iron heme model compound as a simple and effective tool to rapidly probe the structures of the bound complexes formed between the metalloporphyrin and antimalarial drugs from the 4-aminoquinoline, 4-methylenehydroxylquinoline, and 8-aminoquinoline subfamilies. The ability of gallium(III) protoporphyrin IX to mimic heme chemistry is exploited. The 4-aminoquinolines quinacrine and amodiaquine and two novel 3-halo chloroquine analogues are found to bind to the metalloporphyrin through hydrogen-bonding and stacking interactions, while halofantrine and the 4-methylenehydroxylquinolines, quinine and mefloquine bind through the alcohol group of the drug...
July 17, 2017: Inorganic Chemistry
https://www.readbyqxmd.com/read/28646540/animal-embryotoxicity-studies-of-key-non-artemisinin-antimalarials-and-use-in-women-in-the-first-trimester
#20
REVIEW
Robert L Clark
The World Health Organization currently recommends quinine+clindamycin for use against malaria in the first trimester. This may soon change to recommending artemisinin-based combination therapies (standard duration of dosing = 3 days). The non-artemisinin partner drugs include amodiaquine, lumefantrine, mefloquine, piperaquine, sulfadoxine+pyrimethamine, and pyronaridine. For quinine, clindamycin, and mefloquine and the combinations of sulfadoxine+pyrimethamine and artemether+lumefantrine, there are reports (including studies without internal comparison groups) that combined describe 304 to >1100 exposures of women in the first trimester for each drug with no conclusive evidence of adverse effects on pregnancy at therapeutic doses...
June 24, 2017: Birth defects research
keyword
keyword
43325
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"